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The ability to manipulate gene expression promises to be an important tool for the 
management of infectious diseases and genetic disorders. However, a major limitation to 
effective delivery of therapeutic RNA to living cells is the cellular toxicity of 
conventional techniques. Team PANACEA’s research objective was to create new 
reagents based on a novel small-molecule delivery system that uses a modular 
recombinant protein vehicle consisting of a specific ligand coupled to a Hepatitis B 
Virus-derived RNA binding domain (HBV-RBD). Two such recombinant delivery 
proteins were developed: one composed of Interleukin-8, the other consisting of the 
Machupo Virus GP1 protein. The ability of these proteins to deliver RNA to cells were 
then tested. The non-toxic nature of this technology has the potential to overcome 
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Numerous infectious diseases and genetic disorders negatively impact human 
health and are of medical concern. However, the severe side effects of many current 
therapeutic regimens may discourage patients from seeking treatment. One good example 
is cancer. Most treatments employed to combat cancer result in severe side effects and 
other costs that may discourage patients from seeking medical intervention: 19.3% of 
Americans refused treatments such as chemotherapy, radiation, and surgery despite the 
fact that over a third had a medical condition requiring treatment (Gavura, 2012). These 
statistics strongly suggest that there is a need for alternative methods of treatment that 
will be more widely accepted by the general public. Gene therapy represents one such 
form of alternative therapy. Recent surveys have indicated that over 90% of the 
respondents accept gene therapy as a treatment for severe illnesses (Robillard et al., 
2014) 
The field of genetics has made major contributions in helping researchers develop 
alternative treatments for genetic diseases. The ability to alter expression of specific 
genes in specific cells at will is a particularly useful tool that researchers are pursuing to 
achieve this end. However, currently available technologies, such as dendrimers, are too 
toxic to primary cells to be considered for effective treatment; such methods can only be 
used on cancerous cell lines in the laboratory (Yao & Eriksson, 2000). In addition, 
despite the advances in gene therapy technologies, more research is needed to develop 
efficient means of target certain genes in specific cell types. 
 Our research question revolves around the development of an efficient technique 




It is based on the specific molecular interactions between cell-surface associated 
receptors and their ligands that enable receptor-mediated endocytosis of ligands into 
cells. We hypothesized that using receptor-mediated endocytosis to deliver therapeutic 
siRNAs into specific cells will result in measurable changes in the expression of the 
targeted genes. Furthermore, we hypothesized that gene expression changes will occur 
only in cells expressing these receptors. 
 To learn more about this approach to altering gene expression, we studied the 
cellular process of receptor-mediated endocytosis, in which cells engulf substances that 
are bound to receptors on the plasma membrane into the cell, as well as specific receptors 
that are capable of undergoing this process. We also examined the properties of siRNA, 
one of the components of the delivery vehicle we will be developing to achieve alteration 
of gene expression, as well as methods of quantifying our research, including quantitative 
real time polymerase chain reaction (qRT-PCR).  
 The project was divided into three phases. The first phase involved identifying 
appropriate receptor/ligand pairs and cloning desired sequences (i.e. the appropriate 
ligand and an RNA binding domain designed to deliver the therapeutic RNA to cells) into 
the parent expression plasmid. Phase two involved using Pichia yeast to produce 
recombinant proteins, optimizing synthesis of recombinant proteins, and purifying the 
proteins. The third phase involved testing the recombinant delivery protein in cell culture. 
In this phase, the negatively charged siRNA was incubated with the purified protein 
where it bound to the positively charged RNA binding domain through electrostatic 
interactions. Then, the siRNA/protein complex was introduced to the target mammalian 




The research presented herein explores a novel method of delivering therapeutic 
RNAs into cells for the treatment of a wide variety of diseases. This new technology has 
the potential to alter or eliminate the expression of specific genes implicated in disease. 
Since receptor-mediated endocytosis is a natural cellular process, it has the potential to 
avoid side effects that are common among other forms of treatment. Consequently, our 
research and proposed method of gene therapy may one day lead to advances in 





Introduction and Overview 
The ability to alter gene expression in specific cells at will is a powerful tool that 
already has multiple applications. Many current methods used to alter gene expression, 
e.g. electroporation, are extremely toxic to cells. These techniques can only be used on 
robust cancerous cell lines and not on fragile primary cells obtained directly from healthy 
organisms (Niidome et al., 2002).  
A technology initially developed at the National Institutes of Health (NIH) 
promises to give researchers the ability to alter cellular gene expression in a more 
targeted and less toxic manner than current commercially available techniques (Biragyn 
et al., 2013). The technology involves fusing RNA-binding protein domains to small 
protein ligands that bind to known cell surface receptors, allowing researchers to deliver 
therapeutic RNAs into specific cells. This literature review will discuss the mechanisms 
behind this novel technology, including a discussion of receptor-ligand interactions and 
the basic cellular processes that are targeted to alter gene expression. This review will 
also analyze existing gene delivery methods, assess their strengths and weaknesses, and 
discuss how this knowledge can be used to enhance our methodology.  
Small Interfering RNA (siRNA) 
 Small interfering RNAs (siRNAs) are small, single-stranded RNA molecules of 
approximately 21-23 nucleotides in length (Maeda & Sheffield 2009). siRNAs are 
targeted to specific messenger RNA (mRNA) sequences through base-pairing 
interactions in concert with a protein complex called RNA-induced Silencing Complex 




2009). Since mRNA is the intermediary between DNA and protein, degrading a specific 
mRNA will decrease protein production. Using siRNAs to interfere with gene expression 
is known as RNA interference (RNAi) (Chiu & Rana, 2003).  
Understanding the process of RNAi is important for developing the most effective 
methodologies for both laboratory and medical applications. In natural systems, RNAi 
begins with cleavage of double-stranded RNA (dsRNA) to short single-stranded siRNA 
(Chiu & Rana, 2003). The newly made siRNA complexes with RISC, and targets a 
specific mRNA for degradation.  
An important avenue of siRNA research involves efforts to stabilize siRNAs as a 
way to increase the duration of dsRNA mediated gene silencing. To further understand 
the mechanism of RNAi in humans, RNAs can be chemically modified, and the resulting 
effects on RNAi effectiveness examined. One of the most important modifications tested 
the importance of the 2’-OH of the ribonucleotide that distinguishes RNA from DNA 
(Chiu & Rana, 2003). These studies demonstrated that the 2’-OH is not required for 
RNAi, indicating that structural, rather than chemical, properties of siRNA-mRNA 
complexes are the main factors in inducing RNAi. This series of experiments elucidated 
important biochemical properties of functional siRNA. In particular, it highlighted how 
specific chemical changes in siRNA can affect the efficiency of RNAi, and pointed to 
approaches designed to improve the stability and usefulness of siRNA for future RNAi 
applications. 
We chose to utilize siRNA as a component of the delivery vehicle protein as 
opposed to other RNAi agents such as microRNA (miRNA) due to the specificity 




miRNA can have multiple targets, which can potentially lead to undesirable effects of 
gene expression alteration (Lam et al., 2015).  
Receptor-Ligand Interactions 
Receptors are proteins expressed on the surface of cells that allow the cell to 
interact with its external environment. These molecules bind specific ligands, i.e. 
essential nutrients and intercellular signaling molecules. Signaling receptors bind specific 
ligands and ultimately initiate pathways that lead to cellular responses involving changes 
in gene expression. In contrast, transport receptors bind ligands and deliver them to the 
interior of the cells (Shankaran, Resat, & Wiley, 2007). The internalization of the 
receptor-ligand complex is a process known as receptor-mediated endocytosis (RME).  
Cells constantly use RME to internalize necessary extracellular molecules, such 
as iron or cholesterol. Proteins carrying these nutrients are ligands for these receptors. 
Once the receptor binds to its ligand, the receptor will move to a region of the plasma 
membrane containing pits coated with the protein clathrin (Goldstein et al., 1985). The 
clathrin coat helps to deform the plasma membrane, making it easier for the receptors and 
their ligands to be internalized. Once inside, ligands and their cargo can be used by the 
cell.  
The transferrin receptor, which plays an important role in cellular uptake of iron 
from outside of the cell, is an example that illustrates the process of RME (Ponka 1999). 
Transferrin is a protein that binds to two iron ions. When a cell requires iron, it 
upregulates expression of the transferrin receptor. Once at the cell surface, the transferrin 
receptor can bind transferrin and multiple receptors will move to the clathrin-coated pit. 




inside a membrane-bound vesicle. Finally, the vesicle fuses with an endosome. The 
acidic environment of the endosome causes the iron to be released from the transferrin 
and the receptor. The iron is then reduced from Fe3+ to Fe2+ by endosomal reductase and 
exits the endosome through divalent metal transporter-1 (DMT1). This iron may now be 
used by the cell. 
Existing Gene Delivery Methods 
Gene delivery is the process of introducing foreign DNA/RNA into a specific cell. 
Current methods of gene delivery include the use of viral vectors, liposomes, 
electroporation, particle-mediated gene transfer, and microseeding. While these methods 
can successfully deliver selected nucleic acids into cells, each method has undesirable 
features, which include deleterious immune responses, lack of stability and specificity of 
the delivery method, high rates of cell death, and insufficient diffusion into the cell. 
These issues necessitate the development of new, efficient and precise vectors for RNA 
delivery. 
Two types of commonly used viral vectors are based on retroviruses and 
adenoviruses. Retroviral vectors are single-stranded RNA viruses which can be used to 
insert genetic material into cells. The technique of using retroviral vectors was first tested 
by transferring a human growth hormone gene to keratinocytes. Once transduced, the 
keratinocytes secreted the human growth hormone and were able to form an epidermal 
layer when grafted onto mice (Morgan, Barrandon, Green, & Mulligan, 1987). While 
retroviral vectors can potentially result in stable and long-term gene expression, one 




Another disadvantage is that they may cause cell transformation as a result of random 
integration into the host cell chromosomes (Yao & Eriksson, 2000).  
Unlike retroviral vectors, adenoviral vectors are double stranded DNA viruses 
that can infect both dividing and non-dividing cells. They are not incorporated into the 
host chromosomes. However, a major drawback to this method is that the vectors often 
cause strong immune responses against the transformed cells because of the presence of 
viral antigens (Yao & Eriksson, 2000). This immune response can be tragically severe: in 
September 1999, a patient given a high dose of adenoviral vector died because of the 
toxicity (St George, 2003). The precautionary measures required when administering 
adenoviral vectors to treat humans limit the scope of this approach.  
Nonviral gene delivery carriers such as polycationic vectors and protein 
transduction domains have been developed to combat some of the safety risks associated 
with viral vectors. Polycationic vectors such as polythyleneimine have a strong ability to 
bind and deliver plasmid DNA in vitro. However, DNA transfer with polycationic vectors 
in vivo has not been as efficacious, and increased cytotoxicity is observed at high 
concentrations (An & Park, 2013). Protein transduction domains are proteins consisting 
of positively charged amino acids that interact with negatively charged lipids during cell 
membrane penetration. One type of protein transcription domain is the human 
transcription factor Hph-1. This protein transduction domain has demonstrated almost no 
cytotoxicity even at high concentrations, though its transfection efficiency was lower than 
that of polycationic vectors (An & Park, 2013).  
Liposomes are another gene transfer technology. Cationic liposomes are vesicles 




as well as to other negatively charged molecules found on cell surfaces (Branski, Pereira, 
Herndon, & Jeschke, 2007). The effectiveness of this method was initially tested by 
creating a liposomal complex containing the beta-galactosidase gene and topically 
applying it to mouse skin. The liposome successfully carried the gene into the skin. The 
gene was expressed in the epidermis, the dermis, and hair follicles for up to seven days 
after the initial application (Alexander & Akhurst, 1995). Although liposomes are more 
stable than viral vectors and interact more readily with the plasma membrane, some 
constraints on their use include chemical and physical instability, short shelf-lives, and 
non-specific uptake by the cells (Sharma & Sharma, 1997).  
Electroporation is a non-viral gene delivery technique commonly used to transfect 
cells. It involves electrical stimulation that increases the permeability of the plasma 
membranes so that large molecules such as DNA can enter the cell (Lee, Chesnoy, & 
Huang, 2004). One study used electroporation to deliver the TGF-β1 gene into mice. 
TGF-β1 encodes a growth factor that increases rates of wound-healing. Researchers 
found that all aspects of wound healing were enhanced in the mice. However, 
disadvantages to the use of electroporation include high rates of cell death, and therefore, 
the requirement for many cells and relatively large amounts of RNA (Gonzalez, Pfannes, 
Brazas, & Striker, 2007).  
Gene guns, otherwise known as particle-mediated gene transfer, also deliver 
naked DNA to tissues or cells. In this technique, nanoscale gold particles are coated with 
DNA and shot through plasma membranes. This direct penetration allows the DNA to 
reach the cytoplasm and even the nucleus (Niidome & Huang, 2002). One experiment 




keratinocytes (Andree et al., 1994). The wound fluid was later analyzed for hEGF, and 
the results showed that the wounds treated with the DNA-coated gold particles had a 190-
fold increase in EGF concentration compared to the control wounds. They also healed 
20% faster than the controls, and the DNA remained in the wound site for 30 days. This 
experiment indicated that gene gun technology was particularly useful for in-vivo gene 
transfer, such as DNA vaccinations and anti-cancer therapy (Yao & Eriksson, 2000). A 
constraint of this method is that it does not penetrate deep into tissues (Niidome & Huang, 
2002).  
An alternative delivery system that is more efficient than particle-mediated gene 
transfer is called microseeding. Microseeding consists of solid microneedles that are 
attached to a piston. Plasmid DNA is placed on the tips of the needles through tubing 
attached to a syringe. The size of the needles can be adjusted depending on the depth of 
penetration desired for the experiment, thus addressing a limitation of gene guns (Yao & 
Eriksson, 2000). Microseeding is also more effective than gene guns because they do not 
deposit foreign materials, e.g. gold beads, into the cell (Yao & Eriksson, 2000). These 
techniques were compared in experiments treating pig wounds with a plasmid encoding 
human epithelial growth factor (hEGF). The protein concentration of hEGF for each 
method was measured using an Enzyme Linked Immunosorbent Assay (ELISA). The 
assay showed that the expression of hEGF in the microseeded wounds was two to three 
times higher than the expression of the growth factor in the gene gun wounds (Eriksson et 
al., 1998). A drawback to microseeding is that the structure of the devices must be 




site (Reed & Lye, 2004). One device cannot be used to deliver different types of 
therapeutic agents, thus reducing the efficiency.  
Each of these methods has successfully been shown to deliver nucleic acids into 
cells and produce the desired outcome: changes in gene expression. However, these 
techniques all have disadvantages. These problems are the driving forces behind the 
search for new and alternative gene delivery systems that can effectively and efficiently 
transfect therapeutic nucleic acids into cells without damaging the cells or tissues. Our 
project strives to improve the specificity of the gene delivery method, prevent damage to 
the cell, and promote prolonged alteration of gene expression. Our proposed technique 
aims to combat the limitations of these existing methods by exploiting the natural process 
of receptor-mediated endocytosis. Since receptor-mediated endocytosis is a natural 
cellular process, we predict that it will cause less harm to the cell than currently 
employed gene delivery methods (Wileman, Harding, & Stahl, 1985). Additionally, the 
current project will minimize the challenges of specifically targeting the gene of interest 
and preventing transfection of other healthy cells.  
Receptor-Mediated Endocytosis 
Receptor-mediated endocytosis is the uptake of soluble molecules into the cell 
(Wileman, Harding, & Stahl, 1985). For transport receptors, such as those that bind 
transferrin, receptor-mediated endocytosis transports the molecules inside the cell to be 
utilized. With signaling receptors, such as those that bind cytokines (cell signaling 
molecules), endocytosis internalizes the ligands that contain information and creates a 
new stimulus that induces a cellular response (Shankaran, Resat, & Wiley, 2007). Overall, 




surface of the cell to their targets in the interior of the cell. Sometimes the internalized 
receptors are targeted to lysosomes, where they are broken down. In other examples, the 
receptors are recycled back to the plasma membrane (Wileman, Harding, & Stahl, 1985).  
As discussed in Alberts (2008), most receptor-mediated endocytosis depends on 
clathrin. Clathrin is a Y-shaped protein that associates with other proteins to form soccer 
ball-like latticework pits on the cytosol side of the plasma membrane. These structures 
are known as clathrin-coated pits. Clathrin-coated pits contain various receptors on their 
surface and constantly pinch off into the cell. If a ligand is bound to one of these 
receptors, then it is taken into the cell. This form of endocytosis is particularly useful 
because it allows the cell to selectively internalize molecules instead of ingesting every 
molecule in range of the pit.  
Selected Receptor-Ligand Pairs 
As a baseline investigation, we chose to assess the success of this delivery system 
with the receptor CXCR1 and the chemokine Interleukin 8 (IL-8). We chose a 
chemokine/chemokine receptor pair because Biragyn et al. (2013) demonstrated 
successful decreases in gene expression when delivering siRNA through the CCR4 
receptor using a CCL17 delivery vehicle protein. Chemokine IL-8 is expressed 
throughout the body and in different types of cells, particularly by white blood cells of 
the immune system. IL-8 affects cells’ chemical response and induces phagocytosis at 
sites of infection (Garofalo et al., 1996). IL-8 also contributes to angiogenesis, the 
creation of new blood vessels. This process is involved in diseases that deplete or damage 
blood vessels, and it has been linked to treatment for rheumatoid arthritis, tumor growth 




Another receptor-ligand pair that the team examined was the Machupo virus 
(MACV) glycoprotein 1 (GP1), which interacts with the transferrin receptor 1 (TfR1). 
MACV is a pathogenic New World arenavirus that causes hemorrhagic fever and has a 
10-30% fatality rate (Abraham et al., 2009). Arenaviruses are enveloped viruses that 
contain single-stranded and bi-segmented RNA. The glycoprotein complex associated 
with the surface of these viruses has three segments: the stable signal peptide (SSP), GP1, 
and GP2 (Abraham et al., 2009). The segment of interest for this project, GP1, is the 
subunit that attaches to the TfR1 receptor, through which the virus gains entry into the 
cell. The primary role of TfR1 is the uptake of iron into cells through endocytosis 
(Abraham et al., 2010). Studies on the structure of the GP1:TfR1 complex have shown 
that variability in the amino acid sequence in the GP1 subunit corresponds to differences 
in sequences of the TfR1 receptor. This suggests that that the glycoproteins are very 
specific and have adapted to their hosts, thus enhancing their ability to cause human 
disease (Abraham et al., 2010). This receptor-ligand pair is of interest in this project 
because of its lack of specificity: since all cells express TfR1, it is potentially capable of 
delivering therapeutic RNAs to all cells. In addition, there are no currently FDA-
approved treatments to stop the spread of the MACV virus (Radoshitzky et al., 2011). 
Therefore, understanding the interactions between GP1 of MACV and TfR1 and using 
RNA silencing to stimulate gene repression can potentially contribute to the prevention of 
these viral infections and development of new treatments for those already infected.  
Developing the Recombinant Proteins 
 The ligands and attached components were developed through the use of the yeast 




industrial scale expression of recombinant proteins because it is easy to manipulate 
genetically. It also only secretes a limited number of proteins, which simplifies the 
purification of secreted recombinant proteins. (Cregg et. al., 1985). As Pichia is an 
eukaryote, it is able to do protein processing, folding, and post-translational 
modifications. Finally, Pichia generally yields higher expression levels of proteins 
(Higgins, 2001). 
Pichia were transformed with a plasmid that codes for all of the components of 
the delivery vehicle. E. coli, commonly used in recombinant DNA research, is employed 
to replicate the plasmid for further use (Hill et. al., 1986). 
The Project 
The project proposed herein seeks to develop a better way of delivering 
therapeutic siRNAs into specific types of cells. To accomplish this goal, we have 
exploited the natural mechanism of receptor-mediated endocytosis, in which cells 
selectively ingest substances from their environment.  
Cells interact with their environment through plasma membrane-associated 
receptor proteins. Some receptors are expressed on a wide variety of cells, while other 
receptors are specifically expressed on only one kind of cell. Each receptor has a ligand, a 
small specifically shaped molecule to which the receptor will selectively bind.  
When a ligand binds to a receptor, it can initiate a variety of responses. The 
binding can trigger signaling pathways that eventually lead to some sort of cellular 
response, e.g. cell death, proliferation, alteration of gene expression profiles, etc. 




uptake of molecules into a cell, through a process known as receptor-mediated 
endocytosis (Shankaran, Resat, & Wiley, 2007). 
If there was a specific receptor for a specific siRNA, then it would be easy to use 
receptor-mediated endocytosis to deliver that siRNA into a cell and silence genes. 
Unfortunately, no such siRNA receptors are currently known. In order to take advantage 
of receptor-mediated endocytosis, the therapeutic siRNA of choice would have to be 
artificially coupled to a ligand with a known receptor. 
This problem was addressed by Biragyn et al. (2013), who created a technique to 
produce this coupling. A siRNA-binding protein derived from the Hepatitis B virus was 
linked to CCL17, a ligand that binds to the CCR4 receptor on T-cells. The recombinant 
protein was then allowed to bind to siRNAs designed to target the mRNAs encoding IL-
10 or FOXP3. Completed cassettes were tested in vitro and in vivo to examine whether 
these delivery vehicles could effectively decrease IL-10 and FOXP3 expression. It was 
found that these genes were temporarily inactivated for approximately 4 days. Since IL-
10 and FOXP3 are involved in cancer metastasis, downregulating the two proteins was 
sufficient for the investigators to observe changes in cancer metastasis (Biragyn et al., 
2013).  
The Biragyn study was limited to CCR4-expressing T-cells, specifically a well-
established cell line called CEM cells. However, many other kinds of cells are commonly 
used in laboratories, including HEK293T cells, HeLa cells, HUVEC cells, primary 
human fibroblasts, induced pluripotent stem cells, and astrocytes. Specific receptors and 
ligands for each of these cells have been identified in the literature. Since this delivery 




theoretically be modified in order to deliver therapeutic RNAs to a wide variety of cells: 
all that is required is knowledge of a specific receptor expressed on the cell of choice, and 
the ligand with which it interacts. 
Quantifying Gene Silencing 
The use of receptor-mediated endocytosis to introduce therapeutic siRNA into 
cells is a useful approach, particularly when coupled with a recombinant protein designed 
to deliver therapeutic nucleic acids to cells expressing a specific receptor. However, it is 
also important to demonstrate that this procedure is not only able to introduce the siRNA 
into a target cell, but that it can cause changes in one specific gene expression. To ensure 
that the siRNA target a specific gene, siRNAs that have been verified by the 
manufacturer and literature to target only a specific gene will be delivered.  
Two commonly used techniques to assay gene expression are quantitative Real-
Time Polymerase Chain Reaction (qRT-PCR) and Immunoblotting (‘Western Blot’).  
qRT-PCR is a method of quantitatively measuring mRNA abundance. mRNA is 
isolated from a cell, converted to complementary DNA (cDNA) using reverse 
transcriptase enzyme and deoxynucleotides (dNTPs), and amplified hundreds of 
thousands of times using a thermal cycler. The rate of the appearance of a product is 
measured using either a variety of dyes or by hybridization with enzymes that produce 
fluorescence or luminescence. Lastly, the data are used to calculate how much of a 
specific mRNA was originally present in the sample (Freeman, Walker, & Vrana, 1999). 
In contrast to qRT-PCR which detects RNA, Western blotting is a technique that 
detects the proteins produced from mRNA templates. According to Kurien and Scofield 




with polyacrylamide gels. Subsequently, the size separated proteins are transferred from 
the gel to a membrane, effectively making a copy of the gel. The membrane can then be 
probed for specific proteins, typically using antibodies. To detect the bound protein-
antibody complex, fluorescent, luminescent or radioactive tracers are used to produce 
signals that can be detected using X-ray film or charge-coupled devices (CCDs). 
By using qRT-PCR and Western Blotting, the silencing effect of the delivered 
therapeutic RNA can be assessed at two levels: mRNA and protein. 
Comparison with Other Methods of Gene Delivery 
An important advantage of the receptor-mediated endocytosis based method of 
conducting gene therapy is its potential for use with primary cells. Electroporation in 
particular, has a severely adverse effect on cells: it causes many cells to die, requiring 
investigators to start with large amounts of cells and RNA (Gonzalez, Pfannes, Brazas, & 
Striker, 2007). In contrast to electroporation, all cells naturally perform receptor-
mediated endocytosis. Consequently, cells do not have to undergo intensely damaging 
treatments and researchers can potentially alter gene expression even in fragile primary 
cells. 
Particle-mediated gene transfer and microseeding put less stress on cells, but 
particle-mediated gene transfer is not reliable as it cannot fully penetrate a tissue 
(Niidome & Huang, 2002) and deposits foreign gold particles into a cell (Yao & Eriksson, 
2000). Microseeding is more efficient, but still causes “thousands of puncture sites in a 
random fashion” (Eriksson et al., 1998). Receptor-mediated endocytosis, on the other 
hand, does not poke holes in the plasma membrane. Instead, endocytotic vesicles pinch 




Viral vectors and liposomes are relatively gentle techniques, as they do not make 
holes in plasma membranes, and can even be used to alter gene expression in primary 
cells. However, retroviral vectors run the risk of causing cancerous transformation if they 
randomly insert into the wrong gene, while adenoviral vectors can cause a massive 
immune response against the adenovirus surface antigens (Yao & Eriksson, 2000). 
Liposomes can and have been used in vivo without too many side effects. However, they 
only alter gene expression for about a week and are prone to transfecting any cells they 
are introduced to, reducing the precision and selectivity of the technique (Alexander & 
Akhurst, 1995). 
In contrast, if the right receptor is found, the types of recombinant delivery 
vehicle proteins described in the current work potentially have the power to silence gene 
expression in specific types of cell. Although Biragyn et al. (2013) observed gene 
silencing for only four days, they noted that because endocytosed receptors are recycled 
back to the plasma membrane, this technique could be used to treat cells multiple times. 
Conclusion 
 Gene therapy has huge implications for how injury and disease are treated. 
Current gene alteration methods have had some success but are damaging to cells, 
resulting in minimal expression or very short-term effects.  
The goal of this project is to improve the efficiency of gene delivery by utilizing 
components and processes that are naturally employed by cells, including the cell’s 
natural receptors and corresponding ligands. We cataloged receptors and ligands in cells 
of interest, produced a delivery vehicle protein, and tested our selected method of 




This research has potential applications both in simplifying biomedical research 
and in treating a wide range of diseases, including cancers and wounds. As the fear of 
side effects dissuades many people from taking medication, an improved delivery method 
for therapeutic RNA has the potential to be a milder alternative to existing medication 
and could one day significantly improve healthcare and disease treatment. We envision 
this delivery vehicle being used as a laboratory reagent to selectively deliver siRNAs for 
basic research more efficiently than current methods. Additionally, it has the potential to 
be used as a therapeutic agent in treating diseases through changing gene expression in 






The overall methodology (Figure 1) is divided into three main phases– plasmid 
production (Figure 2), recombinant protein production (Figure 3), and transfection.  
E. coli-based Methods 
A linear vector was generated from a previously generated pPIC9 plasmid 
(Invitrogen) containing a sequence encoding TARC between Xho I and Xma I restriction 
sites. To excise the TARC sequence, the plasmid was digested with Xho I and Xma I 
restriction sites and the plasmid backbone was gel purified. 
Sequences coding for human chemokine IL-8 (NM_000584) or Machupo virus-
derived membrane protein glycoprotein 1 (GP1) were fused in frame with a single 
DNA/RNA-binding domain (RBD) of the core antigen of the Hepatitis B Virus (HBV) 
contained in the pPIC9 plasmid backbone. Both sequences were identified using the 
NCBI database and obtained as gBlocks gene fragments from Integrated DNA 
Technologies, Inc. (IDT). Sequences encoding the IL-8 and GP1 sequences fused with 
HPV1-RNA binding domain were cloned using the same Xho I and Xma I restriction sites 
as a fusion with the yeast -factor signal sequence. These sequences were ligated into the 
linear vector backbone to create two plasmids named pPIC9_IL8 (Figure 4) and 
pPIC9_GP1 (Figure 5). 
To confirm successful ligation of the IL-8 and GP1 sequences with their linear 
vector backbones, primers containing the XhoI and XmaI restriction sites were designed 
using ApE software (apesoftware.com). Both forward and reverse primers (Table 1, rows 




coding for IL-8 or GP1 using Polymerase Chain Reaction (PCR). The PCR products for 
both sequences were verified by DNA sequencing (GENEWIZ).  
Highly competent DH5 cells were transformed with the recombinant plasmids 
pPIC9_IL8 and pPIC9_GP1. The cells were spread into petri dishes containing 1% agar, 
Lauria broth, and 50 µg/mL carbenicillin to select for transformants. After incubation, 
colonies were picked and spotted onto their respective master plates. Subsequently, each 
respective colony was grown in liquid culture overnight, after which the candidate 
pPIC9_IL8 and pPIC9_GP1 plasmids were extracted. Intact plasmids were initially 
separated through 1% agarose gels to verify that intact plasmids were maintained in the 
DH5 cells. Plasmids were digested using Xho I and Xma I and run through a second 1% 
agarose gel to screen for recombinant plasmids. Only colonies with 297 bp fragments 
corresponding to IL-8, and 488 bp fragments corresponding to GP1 were selected for 
transformation into Pichia. The plasmid harboring the IL8-based construct was named 
pJD1965, and the plasmid harboring the GP1-based construct was named pJD1966. 
Bacterial strains harboring these plasmids were stored in glycerol at -80°C. 
Successfully transformed E. coli containing pJD1965 (IL-8) and pJD1966 (GP1) 
were removed from -80°C storage and streaked onto for single colonies onto two LB 
plates containing 30 µg/mL of carbenicillin and incubated overnight at 37°C. Single 
colonies from each were inoculated in several LB culture tubes containing 30 µg/mL 
carbenicillin to ensure selection for the plasmids. The cultures were grown for twelve 
hours in a 37°C shaker. Plasmids were extracted using Maxiprep kit (Qiagen). The 
extracted plasmids were linearized using Sal I and compared to undigested plasmids 




with ethanol and stored at -20°C. This process was repeated multiple times to produce a 
sufficient amount of the plasmids. 
Pichia pastoris-based Methods 
The methanol-inducible Pichia Pastoris expression kit from Invitrogen was used 
to produce both recombinant proteins. The proteins produced from pJD1965 were named 
IL8-ARP and the proteins produced from pJD-1966 were named GP1-ARP.  
The GS115 strain Pichia pastoris was transformed with linearized pJD1965 and 
pJD1966 based on the Invitrogen protocols. Freshly grown GS115 Pichia Pastoris 
containing a defective his4 gene were streaked onto YPAD plates and grown at 30°C. 
Colonies were inoculated into YPAD liquid media and serially passaged for another three 
days. Each day, colonies were inoculated into fresh YPAD media.  
The LiCl method was used to transform the GS115. The cells were pelleted by 
centrifugation, supernatant was decanted, and the cell pellet was suspended in 1 mL of 
100 mM LiCl. The cells were pelleted by centrifugation and LiCl was removed with 
pipet. The cells were resuspended in 400 uL of 100 mM LiCl and pelleted by 
centrifugation a third time. The LiCl was removed with pipet. 
For all samples, 240 L of 50% PEG-3350, 36 L of 1M LiCl, and 25 L of 
single-stranded fragmented salmon sperm DNA (2 mg/mL), and 50 L of plasmid (100-
200 ng/L) were added in the order listed. As a negative control, 50 L sterile water was 
used in place of the plasmid. As a positive control, yeast previously transformed with 
TARC were subjected to the same transformation process with 50 L sterile water 




All samples were incubated in a 30°C water bath for one hour, then heat-shocked 
in a 42°C water bath. Tubes containing the cells were gently inverted every 10 minutes to 
prevent mixtures from separating. The cells were then streaked on solid media plates 
containing synthetic complete media lacking histidine (SD –His) and were grown in a 
30°C incubator for three days. 
The individual His+ colonies were streaked to a –His master plate. Each 
transformed colony was grown in –His media for three days. The genomic DNA samples 
were extracted based on the Smash and Grab method and stored at -20°C (Rose, Winston 
& Hieter, 1990).To identify colonies in which the linearized plasmids had integrated into 
the HIS4 locus, polymerase chain reactions were performed with Taq polymerase master 
mix (Thermo Scientific) and primers for PIC9-IL8 and PIC-GP1 (Table 1, rows 5–8). 
PCR results were visualized using gel electrophoresis to identify colonies in which 
plasmid insertions into the his4 loci on both chromosomes had occurred. All the “double 
insertion” colonies were amplified in liquid –His media and stored in 50% glycerol at -
80°C for later use. The three PIC9-IL8 colonies were named YJD 1711-1713, and the 
two PIC-GP1 colonies were named YJD 1714-1715.  
Protein Production 
The frozen double insert colonies were streaked onto –His plates, and after three 
days growth, single colonies were picked and grown in 5 mL of liquid –His media for 
two additional days at 30°C. The Pichia were transferred to 2L baffled flasks containing 
500 mL YPAD and grown for 18-24 hours to an O.D. 600 nm of 4-7. The cells were 
pelleted by centrifugation and the YPAD supernatant discarded. The pellet was re-




(0.02% biotin), 50 mL 10X methanol (5% methanol), and 50 mL 10X Yeast Nitrogen 
Base with ammonium sulfate and without amino acids (13.4% YNB). The new mixture 
was incubated in a 30°C shaker for six hours. Subsequently, recombinant protein 
production was induced by pumping 100% methanol into the cultures at a rate of 9 
microliters/minute for 36 hours at 30°C. Because the delivery vehicle plasmid has a 
methanol-inducible promoter, pumping methanol induced the yeast to produce the 
recombinant protein. Furthermore, because the delivery vehicle plasmid also has a 
secretion signal, the recombinant protein was secreted into the media.  
Protein Purification 
 After undergoing 36 hour induction of recombinant protein production, the yeast 
cultures were centrifuged and the supernatants containing the recombinant proteins were 
decanted and filtered through bottle-top filters with PES membranes and 0.22 M pore 
size (Fisher). 25 mL of 2.0 M NaPO4 (pH 8.0) was added to every 2L of supernatant to 
bring the pH to approximately 7.0. The supernatant was decanted into a 2L separatory 
funnel connected to the separation column containing SP sepharose (Sigma Aldrich) 
(Figure 6).  
The supernatants were allowed to pass through the column, which, due to its net 
negative charge, bound the recombinant proteins through non-covalent interactions with 
their positively charged RNA binding domains. Non-specifically bound proteins were 
eluted from columns using wash buffer (0.15 M NaCl, 0.05 M NaPO4, pH 8.0). The 
recombinant proteins were eluted from columns with high salt elution buffer (1 M NaCl, 




Filter Devices, stored in 30 L aliquots, flash frozen in liquid nitrogen, and stored at -
80°C. The concentration of the proteins was measured using the Bradford assay.  
SDS-PAGE 
 Both purified recombinant proteins were separated using 12.5% SDS-PAGE gels 
to confirm the proteins’ sizes were correct. PageRuler Prestained Protein Ladder (Thermo 
Scientific) was used to confirm the size of the two delivery vehicle proteins.  
Testing Recombinant Protein 
 The ability of the recombinant proteins to deliver small RNA cargos was assayed 
in suspension cell culture and adherent cell culture systems. 
Suspension Cell Culture 
CEM cells were cultured in RPMI-1640 ++ media (10% Fetal Bovine Serum, 1X 
Penicillin and Streptomycin) on untreated culture flasks under sterile conditions in a 
tissue culture hood. Cells were incubated at 37°C and were transferred to fresh media 
every 2-3 days.  
Suspension Cell Transfection Protocol 
CEM cells were used for suspension cell transfection experiments. CEM cells 
were chosen because they express both the transferrin receptor and CXCR1, the IL-8 
receptor. Thus, they are suitable for transfection with both GP1-ARP and IL8-ARP. 
The day before transfection, cells were spun down and resuspended in fresh 
media to a concentration of 5x105 – 7x105 cells/mL. The day of transfection, cells were 
spun down and resuspended to a concentration of 1x106 cells/mL. 250 L cells were 




The transfection reagent mix was prepared the day of transfection (250 L 
reagent per well). To make the transfection mix, 2 L 20 M siRNA were added to 246 
L RPMI-1640 (No FBS, no antibiotics. Then, 2 L of HiPerfect (Qiagen) or 2 ng of 
recombinant protein were added to the siRNA and RPMI mixture. AllStars Hs Cell Death 
Control siRNA (Qiagen) was used as the experimental siRNA. AllStars Negative Control 
siRNA (Qiagen) was used as the negative control siRNA.  
Transfection reagents were incubated for 15-20 min at room temperature in the 
tissue culture hood. 250 L of transfection reagent were subsequently added to each well. 
The cells were incubated at 37°C and samples were taken for analysis at specific time 
points (12, 24, 48 hours). 
Adherent Cell Culture 
HEK 293T cells were cultured in DMEM++ media (10% Fetal Bovine Serum, 1X 
Penicillin and Streptomycin) on treated culture flasks under sterile conditions in a tissue 
culture hood. Cells were incubated at 37°C and split once they reached 80% confluency. 
Adherent Cell Transfection Protocol 
 1x105 cells were seeded into each well of a 48-well treated plate and allowed to 
grow overnight until they reached 70-90% confluency. Before transfection, the old media 
was replaced with fresh DMEM++. 
The transfection reagent mix was prepared the day of transfection (250 L 
reagent per well). To make the transfection mix, 2 L 20 M siRNA were added to 246 
L DMEM (No FBS, no antibiotics. Then, 2 L of HiPerfect (Qiagen) or 2 ng of 




Death Control siRNA (Qiagen) was used as the experimental siRNA. AllStars Negative 
Control siRNA (Qiagen) was used as the negative control siRNA.  
Transfection reagents were incubated for 15-20 min at room temperature in the 
tissue culture hood and added by drops to each well. The cells were incubated at 37°C for 
the appropriate time points (12, 24, 48 hours). Before harvesting, cells were examined 
under a light microscope for signs of stress. Cells were trypsinized and harvested from 
the plate.  
Quantifying Transfection 
The fraction of live cells was assayed at 12, 24, and 48 hour time points. Cells 







Cloning of IL-8 and Machupo Virus GP1 Sequences Into pIC9 
The IL-8 and GP1 gene sequences were successfully cloned into the Xho I and 
Xma I restriction sites of pPIC9. The pPIC9_IL8 plasmid map (Figure 4) shows the 
location of the newly inserted IL-8 gene sequence in the pPIC9 backbone. Similarly, the 
pPIC9_GP1 plasmid map (Figure 5) shows the location of the newly inserted GP1 gene 
sequence in the pPIC9 backbone.  
Sequential digestion of the pPIC9_IL8 and pPIC9_GP1 plasmids with the XhoI 
and XmaI restriction enzymes shows two distinct bands on the 1% agarose gel (Figure 7). 
The IL-8 insert migrated through the gel as an approximately 300 bp fragment and the 
GP1 fragment migrated as about a 500 bp fragment. The actual base pair lengths of the 
IL-8 and GP1 inserts are 297 bp and 488 bp, respectively.  
Plasmid Linearization and Pichia Transformation 
The plasmids contained within each E.coli strain conferred resistance to 
carbenicillin. Through this, we ensured that selective pressure drove retention of 
plasmids. After the plasmids were extracted, purified, and linearized with Sal I (Thermo 
Scientific), agarose gel electrophoresis confirmed that the plasmid was linearized (Figure 
8). The supercoiled DNA of unlinearized plasmids is visible in lanes 6 and 7, while the 
linearized plasmids in lanes 2 through 5 show singular bands at of the expected sizes.  
The plasmids were then integrated in to yeast genome through homologous 
recombination into the his4 locus. The transformed colonies were selected for on –His 




medium. PCR analysis further confirmed that the sequence of the protein vehicle was 
integrated successfully. After extraction and purification of genomic DNA from the 
transformed cells, PCR was used to amplify sequences near the IL-8/GP1 protein 
sequence (Table 1, rows 3 and 4). The PCR results suggest that the amplified sequence 
contained the correct sequence inserted into the his4 loci of the transformed cells (Figure 
10 and Figure 11). The negative control, i.e. untransformed GS115 cells, showed no PCR 
product (lane 14) because this genome lacks sequences complementary to the primer 
sites. The positive control, i.e. pure plasmids, shows these PCR products (lane 13). 
Because Pichia is diploid, it is possible for plasmid integration to occur at one, the other 
or both his4 loci. The double insertions colonies can be identified by the presence of only 
the larger PCR products, i.e. lanes 4, 6, and 11, while the presence of two bands indicates 
integration into only one of the his4 loci.  
Verification of Recombinant Protein 
Protein concentrations were measured using the Bradford Assay. Concentrations 
ranged from 700 g/mL to 2700 g/mL, but most batches of proteins produced were at a 
concentration of 1000 g/mL. 
SDS-PAGE was performed on the proteins to check their size. The IL-8 delivery 
vehicle protein is visible in a band that roughly matches the 11 kDa size of the IL-8 
protein (Figure 12, lanes 4 through 6). The GP1 delivery vehicle protein is visible in a 
band approximately 11 kDa (Figure 12, lanes 2 and 3), which does not match the size of 
the GP1 protein (22 kDa). There is a faint 22 kDa band on the first sample of GP1 
(Figure 12, lane 2), which may indicate the protein was degraded or the protein was 




of the GP1 recombinant protein to induce receptor-mediated endocytosis, which was why 
it was tested in cell culture.  
Transfection Experiment Results 
Preliminary CEM cell experiments produced highly variable results (Figure 13). 
The cells transfected with delivery vehicle protein and cell-death inducing siRNA did not 
die at a significantly higher rate. However, the HiPerfect positive control was also unable 
to successfully deliver cell-death inducing siRNA.  
Preliminary HEK293T cell experiments produced promising results (Figure 14). 
At 24 hours post-transfection, the cells transfected with the GP1 delivery vehicle protein 
and cell death siRNA had lower viability than cells transfected with the GP1 delivery 
vehicle protein and scrambled siRNA negative control. At 48 hours, there were no 






The sequences for the IL-8 and GP1 HPV1-RNA binding protein delivery 
vehicles were successfully inserted and retained in the plasmids, which were then 
transfected into yeast. The histidine selectable marker in the DNA of the plasmids 
ensured that only colonies containing the plasmids were able to grow. The methanol 
inducible promoter included in the sequences of the plasmids initiated the production of 
the proteins in the presence of methanol and the secretion signal facilitated their release 
from the cells. Achieving successful transformations of the correct sequences to produce 
the proteins signified a marked improvement in technique optimization. 
Limitations 
There are some important limitations to our methodology that remain to be 
addressed. We only had a year and a half to complete the research portion of our project. 
With this limited amount of time, we were not able to test a large variety of receptor-
ligand and cell type combinations as would be preferred. However, the two ligands we 
studied met our goal of initiating the development of a catalogue of working receptor-
ligand-cell combinations that will be later expanded upon by other researchers.  
 Another limitation of our methodology is that the uptake of RNA into the cell 
depends on a protein ligand interacting with a cell surface receptor. There are many types 
of ligands including protein, hormone, and sugar ligands, but because of the way we 
created our cassette, only proteins could be ligated. This somewhat limits this method of 
RNA delivery and lessens its versatility as a method for gene therapy. However, since 
there are hundreds of known protein ligand-receptor combinations, there are still a wide 




 The greatest limitation to our project is that it was done in vitro, which does not 
accurately simulate the conditions of the human body. The whole point of the utility of 
this method of RNA delivery is that the only cells that should be affected by the treatment 
are those that express a surface receptor that binds to the ligand of the delivery vehicle. 
This allows for targeted delivery of siRNA to only certain cell types, something current 
gene delivery methods lack. We tested the efficiency of our RNA delivery vehicle in a 
medium containing cells ranging from a single cell type to three or four cell types. This 
did not completely simulate the environment of the human body and the results we 
obtained from these test may be different than what would happen in vivo. However, this 
is an issue that can easily be addressed by future research once it is proven that this RNA 
delivery method works effectively for singular cell types.  
Challenges 
We had to overcome several hurdles throughout the course of this project. We had 
trouble creating the plasmids for the recombinant proteins as the starting pPIC9 plasmid 
was very large. Its size made it difficult to achieve successful transformations in E. coli. 
We had the same problem when transfecting Pichia with these clones. It took several 
months to create Pichia strains that successfully integrated our linearized plasmids. On 
several occasions, improper handling of reagents led to successful clones dying before 
they could be properly stored, setting the project back months at a time. 
Our second major challenge lay in protein production, as our GP1 protein was 
about 10 kDa too short. In this project, we verified insertion of the GP1 plasmid into 




HIS4 locus are needed. Protein folding studies to determine proper folding of the ligand 
part of the delivery vehicle protein could also be helpful.  
Additional RNA binding assays to determine the binding kinetics of the 
recombinant protein could be also useful in troubleshooting, as would studies to visualize 
the release of siRNA once the delivery vehicle protein-siRNA complex is internalized 
into the cell.  
Our last major challenge lay in optimizing the design of our initial transfection 
experiments. The first experiments involved transfecting CEM cells with AGO1 siRNA 
to reduce expression of the AGO1 gene. Because AGO1 is part of the RNA interference 
pathway, knocking down AGO1 led to unanticipated downstream effects and 
inconclusive data about the success of the transfection.  
To overcome these challenges, we shifted the focus of the project slightly. Instead 
of delivering AGO1 siRNA, we delivered apoptosis-inducing siRNA. The benefits of 
delivering apoptotic siRNA were two-fold. First, there are no unknown effects to 
apoptosing cells, as cells can only remain alive or die. The second benefit was a 
significantly expedited analysis of our transfection experiments. To analyze the AGO1 
siRNA experiments, we had to extract mRNA and quantify levels of AGO1 mRNA 
through qRT-PCR, a very time-consuming and labor-intensive process. In contrast, for 
the cell death siRNA transfections, we were able to simply measure the percentage of live 
cells. This relative ease of analysis allowed us to take measurements and get a more 
detailed look at the effect of our protein over time.  
We had additional trouble with the CEM cells, which are notoriously difficult to 




using a commercial reagent as a positive control, only a fraction of the initial CEM 
transfections were successful. Also, the Trypan Blue assay used to measure CEM cell 
viability may have under-measured the percentage of dead cells. Due to these limitations, 
we moved to testing the recombinant delivery vehicle protein in HEK293T cell culture, 
which produced promising results at 24 hours post-transfection.  
As our cell culture experiments were in their preliminary stages, further 
optimization of siRNA concentrations, protein concentrations are needed. Additional 
experiments to determine why the HiPerfect positive control was not working, or 
experiments using a different positive control reagent, are also needed. The time points 
measured also need to be optimized. The HEK293T cells showed significant decreases in 
cell viability 24 hours post-transfection, but not 48 hours post-transfection. One 
explanation for these results could be that the cells recovered from the first delivery of 
cell-death inducing siRNA by the 48 hour time point. Therefore, the optimal window to 
measure transfection efficacy needs to be determined. Finally, experiments with multiple 
deliveries of siRNA could also be highly informative.  
Significance of Research 
This research project enhanced the specificity of techniques altering gene 
expression so that only particular cells of interest would be targeted. Existing treatments, 
i.e. chemotherapy, target cells that share similar characteristics, which result in healthy 
cells also being killed by the treatment. By studying the IL8 receptor and ligand, we 
aimed to demonstrate the specificity of the delivery vehicle protein and turn off gene 
expression only in cells containing the IL8 receptor. The specificity of this receptor-




receptor found on all cells. By identifying receptors specific to particular cells, 
therapeutic RNAs can be utilized to target solely those cells, thereby preventing harm to 
other healthy cells. In cancer treatment, this technology can be used to target a receptor 
only found on the tumor cells, which will allow other fast-growing cells such as hair cells 
targeted in current treatments to survive.  
Furthermore, as mentioned earlier existing gene therapy techniques can cause 
significant changes to the cell, i.e. damage to the membrane or cell death. The developed 
protein described in this paper prevents these harmful side effects by utilizing the process 
of receptor-mediated endocytosis in order to be internalized into the targeted cell. Since 
this is a natural cellular process, it is less likely cause damage to the cell. Studies have 
shown that receptor-mediated endosomal uptake of therapeutic RNAs is the most 
efficient uptake pathway since it eliminates the risk of cell membrane disruptions by 
direct cell membrane penetration methods (Haussecker 2014). Thus, not only does the 
developed delivery vehicle protein contribute to the specificity of gene expression 
alteration, it also promises more efficient delivery of therapeutic RNA.  
Future Directions 
The next step in advancing this technology is to expand the catalogue of receptor-
ligand pairs that have been tested. As data is gathered on receptors of additional cell 
types, the technology can be applied to an expanding number of disease states in the 
body. For example, Chemokine Receptor type 4 (CXCR4) is involved in many disease 
states including 23 types of cancer and several immunodeficiency disorders. In the 
example of cancer, when cancer cells express CXCR4, the receptor is still able to interact 




allows for the growth and spread of tumors. By using receptor-ligand interaction, we can 
introduce RNA that inhibits CXCL12 receptors, which will in turn stop the growth and 
spread of tumor cells.  
This method can also be applied where other forms of gene therapy have not been 
effective. For example, mutations in skin grafts produced as a result of retroviral vectors 
could be avoided by treating existing cells to minimize damage to the skin (Yao and 
Eriksson, 2000). Another common method, electroporation, used to deliver skin-healing 
growth factors (Lee, Chesnoy, & Huang, 2004), resulted in high rates of cell death that 
could be avoided by this method, which is much gentler because it utilizes natural cell 
processes (Gonzalez, Pfannes, Brazas, & Striker, 2007). As this technology is expanded, 
it must also be optimized.  
Another possible optimization comes from the ligand. There are many smaller 
peptides and molecules that can bind to receptors on cell surfaces as well as the full 
length peptides of our ligands. For example, OX26, a transferrin receptor monoclonal 
antibody, could be used instead of GP1 for binding to transferring receptor. The OX26 
has been used extensively in similar delivery into cells with transferrin receptor (Ulbrich 
et al., 2009). The ligand has smaller size than natural ligand, as well as having higher 
binding affinity. 
Following many iterations and significant testing over the course of the next few 
years, the project will be developed enough to consider its clinical applications. One 
rising clinical application of gene therapy is ex vivo treatment, removing cells from the 
body to treat them with gene therapy and then replacing the healthy cells into the body, 




2002). When ex vivo methods are not yielding positive results, another growing use in 
treatment is intraoperative gene therapy (Mann et al., 1999). Progression toward clinical 
applications will also include validating the specificity of the treatment in vivo. One 
approach to increasing the reach of the project is to produce the protein commercially as 
an intermediate step. This way it can be marketed for in vitro laboratory uses in order to 
receive feedback that can contribute to the optimization of the technology. The 
mechanism for marketing the product exists in the framework of Birich Tech, the start-up 





Appendix A: Figures and Tables 
Figure 1 
 






















Plasmid map of newly cloned PIC9_IL8 plasmid containing Interleukin 8 sequence. 













Plasmid map of newly cloned PIC9_GP1 plasmid containing Glycoprotein 1 sequence. 































Lane 1: 1 kb ladder; Lane 2: pPIC9_IL8 double digested; Lane 3: pPIC9_GP1 double 
digested. Both lanes 2 and 3 were double digested with Xho I and Xma I. The expected 







Linearized plasmids on a 1% electrophoresis gel. Lane 1 shows the MassRuler DNA 
Ladder Mix from Thermo Scientific. Lane 2 and 3 contain linearized PIC9-IL8, which 
matches the actual size of the digested PIC9-IL8 (8368 bp). Lane 4 and 5 contain 
linearized PIC9-GP1, which matches the actual size of PIC9-GP1 (8611 bp). The Sal1 
digest enzyme was used to linearize all plasmids. Lane 6 contains unlinearized PIC9-IL8, 








Transformation of GS115 Pichia, plated on –His plates. (A) Previously successfully 
transformed Pichia containing TARC. The cells already were able to grow in 
environment without histidine, and were used as positive control. The red coloring 
indicates overgrowth. (B) Mock-transformed Pichia. These Pichia were used as a 
negative control. There was no growth, as no plasmids were added to cells during 









PCR of GS115 Pichia transformed with pPIC9-IL8. Lane 1 shows the MassRuler DNA 
Ladder Mix from Thermo Scientific. Lanes 2 through 12 are transformed colonies. Lanes 
4, 6, and 11 show colonies with the pPIC9-IL8 plasmid inserted on both chromosomes 
(double insertion). Lane 13 shows the original plasmid, used here as the positive control. 








PCR ofGS115 Pichia transformed with pPIC9-GP1. Lane 1 shows the MassRuler DNA 
Ladder Mix from Thermo Scientific. Lanes 2 – 11 are transformed colonies. Lane 5 and 6 
show colonies with the GP1 plasmid inserted on both chromosomes. Lane 12 shows the 
original pPIC9-GP1 plasmid, used here as the positive control. Lane 13 contains the 








SDS PAGE was performed on all batches of delivery vehicle protein produced to confirm 
expected size. Lane 1 and 2, ladder. Lane 3 through 5, IL8-ARP. Lane 8 and 9, GP1-
ARP. The IL-8 ARP bands approximately match the 11kDa expected size of IL-8 







CEM cells were transfected with HiPerfect, a commercially available transfection 
reagent, as a positive control. CEM cells were also transfected with delivery vehicle 
proteins GP1-ARP and IL8-ARP. A scrambled RNA sequence (Scr) with no biological 
activity was used as a negative control. AllStars Cell Death siRNA (AllStars), a 
commercially available cell-death reagent, was used as the experimental siRNA. Cell 
Viability was determined by counting the fraction of live cells in Trypan blue. (A) depicts 
CEM cell viability 12 hours post-transfection, (B) depicts viability 24 hours post-
transfection, and (C) depicts viability 48 hours post-transfection.  







HEK293T cells were transfected with HiPerfect, a commercially available transfection 
reagent, as a positive control. HEK293T cells were also transfected with delivery vehicle 
proteins GP1-ARP. A scrambled RNA sequence (Scr) with no biological activity was 
used as a negative control. AllStars Cell Death siRNA (AllStars), a commercially 
available cell-death reagent, was used as the experimental siRNA. Cell Viability was 
determined by counting the fraction of live cells in Trypan blue. (A) depicts HEK293T 
cell viability 24 hours post-transfection, (B) depicts viability 48 hours post-transfection. 






Oligo Name Target Plasmid Sequence 5’ to 3’ 
5’XhoI to XmaI Primer pPIC9_IL8 and pPIC9_GP1 actattgccagcattgctg 
3’XhoI to XmaI Primer pPIC9_IL8 and pPIC9_GP1 ttctacgcgattgagacctt 
5’ AOX1 Primer PIC-IL8 and PIC-GP1 gactggttccaattgacaagc 
3’ AOX1 Primer PIC-IL8 and PIC-GP1 ggatgtcagaatgccatttgc 
5’ IL-8 Primer PIC-IL8 atgacttccaagctggcc 
3’ IL-8 Primer PIC-IL8 tgaagagggctgagaattca 
5’ GP1 Primer PIC-GP1 agacttttagctaaccattcaaatga 
3’ GP1 Primer PIC-GP1 gaagtaagacacatctcaactttgaa 






Appendix B: Glossary 
 
Adenovirus (n) – Any of a group of DNA-containing viruses that cause conjunctivitis 
and upper respiratory tract infections in humans (thefreedictionary.com) 
 
Adherent cell line (n) – cells that continue to grow in vitro until they have covered the 
available surface area (sigmaaldrich.com) 
 
Allele (n) – a member of a pair of genes that is located on an important portion of the 
chromosome (freedictionary.com) 
 
Anion Affinity Column (n) – a chromatographic technique in which biological 
molecules bind reversibly to ligands of a negative charge on the column 
(freedictionary.com) 
 
Antigen (n) – any substance that, when injected into the body, will cause the body to 
produce antigens. Common antigens include toxins, bacteria, and implanted organ cells 
(freedictionary.com) 
 
Antisense strand (n) – A strand of nucleotide sequence that is complementary to the 
messenger RNA (mRNA) (freedictionary.com) 
 





Bradford Assay (n) – a spectroscopic technique that measures the concentration of all 
proteins in a solution (freedictionary.com)  
 
Cassette (n) – A DNA sequence encoding multiple genes of interest between one or 
more sets of restriction sites (freedictionary.com) 
 
CEM cells (n) – a human T cell lymphoblast-like cell line (abcam.com) 
 
Consumption controlled (adj) – response control depends on the ability to internalize 
surface-bound ligand (freedictionary.com) 
 
Cytokines (n) – regulatory proteins that are released by the immune system to act as 
messengers between cells during a immunological response (freedictionary.com) 
 
Endocytosis (n) – Process in which the cell brings substances past the membrane and 
into itself through the folding of the plasma membrane (freedictionary.com) 
 
Escherichia coli (n) – a rod-shaped bacterium commonly used in recombinant DNA 
research (freedictionary.com) 
 
Enzyme-Linked Immunosorbent Assay (ELISA) (n) – an assay that uses an enzyme 





Glycoprotein 1 (n) – a protein found in the Machupo virus that binds to the transferrin 
receptor (uniprot.org) 
 
Growth factors (n) – any protein within the cell that supports the growth, organization, 
and maintenance of the cell; large amount of growth factor could lead to cancer 
(freedictionary.com) 
 
HEK293T cells (n) – cells derived from the human embryonic kidney cell line 293 and 
commonly used in transfections (freedictionary.com) 
 
Homologous recombination (n) – A type of genetic recombination is which sequences 
of nucleotides are exchanged between two similar segments of DNA (everythingbio.com) 
 
Interleukin 8 (n) – a cytokine produced by different cell types that activates neutrophils 
and is involved in inflammation (free dictionary.com) 
 
Interleukin 8 receptor/CXCR1 (n) – a receptor found on neutrophils that selectively 
binds interleukin 8 (freedictionary.com) 
 
Keratinocytes (n) – the predominant cell in the epidermis, the outermost layer of the 





Ligands (n) – Proteins that bind to the receptor sites of the cell (freedictionary.com) 
 
Lipoprotein (n) – a structure on the cell membrane that regulates water flow into and out 
of the cell (freedictionary.com) 
 
Lysosomes (n) – an organelle of the cell that breaks down unneeded substances, like 
worn organelles and food particles, and harmful substance, like bacteria and viruses 
(freedictionary.com) 
 
Messenger RNA/mRNA (n) – RNA that is transcribed from DNA in the nucleus and 
moves to the cytoplasm, where it is translated to protein (freedictionary.com) 
 
Mid-Logarithmic Phase (n) – The phase in the growth of a cell culture characterized by 
cells doubling with each successive round of replication (masfield.osu.edu). This phase is 
the time when cells most efficiently take up plasmid DNA (goldiesroom.org) 
 
Nucleotide (n) – Any of various compounds consisting of a nucleoside combined with a 
phosphate group and forming the basic constituent of DNA and RNA 
(thefreedictionary.com) 
 
Plasmid (n) – A circular, double-stranded unit of DNA that replicates within a cell 




are used in recombinant DNA research to transfer genes between cells 
(freedictionary.com) 
 
Pichia pastoris (n) – a species of yeast used for protein production using recombinant 
DNA (pichia.com) 
 
Polymerase Chain Reaction/PCR (n) – A technique for amplifying DNA sequences in 
vitro by separating the DNA into two strands and incubating it with oligonucleotide 
primers and DNA polymerase (freedictionary.com)  
 
Quantitative Real-Time Polymerase Chain Reaction/qRT-PCR (n) – A method for 
quantifying the amount of a specific RNA sequence (freedictionary.com) 
 
Recombinant DNA (n) – DNA molecules that are extracted from different sources and 
chemically joined together. For example, DNA comprising an animal gene may be 
recombined with DNA from a bacterium (free dictionary.com) 
 
Recombinant Protein (n) – a protein derived from genetically engineered DNA 
(freedictionary.com) 
 
Restriction Enzymes (n) – Enzymes that cut nucleic acids at specific sites on the strand 





Ribonucleotide (n) – The basic building block of RNA (freedictionary.com) 
 
RNA binding domain (n) – a region of RNA binding proteins that binds to double or 
single-stranded RNA in cells (nlm.nih.gov) 
 
Small RNA (n) – RNA such as small interfering RNA or microRNA that dynamically 
represses gene expression (Journal of Cell Science) 
 
Small interfering RNA (siRNA) (n) – A type of small RNA that requires complete 
complimentary sequence to silence the matching mRNA strand (Journal of Cell Science) 
 
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis/SDS-PAGE (n) – The 
separation of proteins by migration through a solution under the influence of an applied 
electric field. Proteins are treated with SDS reagent to linearize them and give them a 
negative charge (freedictionary.com) 
 
Supernatant (n) – The liquid lying above a solid residue after crystallization, 
precipitation, centrifugation, or other process (google.com) 
 
Transcribe (v) – To find corresponding messenger RNA (mRNA) nucleotide sequence 
that matches a particular sequence of DNA; reverse transcribe is the transcription of 





Transferrin (n) – iron-binding glycoproteins that control the level of iron in the blood 
(freedictionary.com) 
 
Transferrin receptor 1/TfR1 (n) – A receptor that mediates the uptake of iron from 
transferrin into the cell via endocytosis (Journal of Biochemistry and Cell Biology) 
 
Vector (n) – A bacteriophage, plasmid, or other agent that transfers genetic material from 




Appendix C: Protocols 
Gibson Assembly Protocol* (Gibson, 2013) 
1. Prepare 5X ISO buffer. Six mL of this buffer can be prepared by combining the 
following: 
3 ml of 1 M Tris-HCl pH 7.5 
150 μl of 2 M MgCl2 
60 μl of 100 mMdGTP 
60 μl of 100 mMdATP 
60 μl of 100 mMdTTP 
60 μl of 100 mMdCTP 
300 μl of 1 M DTT  
1.5 g PEG-8000 
300 μl of 100 mM NAD 
Add water to 6 ml 
Aliquot 100 μl and store at -20 °C 
2. Prepare an assembly master mix. Combining the following: 




0.64 μl of 10 U/ μl T5 exo 
20 μl of 2 U/μl Phusion pol 
160 μl of 40 U/μl Taqlig 
Add water to 1.2 ml 
Aliquot 15 μl and store at -20 °C. This assembly mixture can be stored at -20 °C for at 
least one year. The enzymes remain active following at least 10 freeze-thaw cycles. This 
mixture is ideal for the assembly of DNA molecules with 20-150 bp overlaps.  
3. Thaw a 15 μl assembly mixture aliquot and keep on ice until ready to be used. 
4. Add 5 μl of DNA to be assembled to the master mixture. The DNA should be in 
equimolar amounts. Use 10-100 ng of each ~6 kb DNA fragment. For larger DNA 
segments, increasingly proportionate amounts of DNA should be added (e.g. 250 ng of 
each 150 kb DNA segment). 
5. Incubate at 50 °C for 15 to 60 min (60 min is optimal). 
6. If cloning is desired, electroporate 1 μl of the assembly reaction into 30 μl 





Mammalian Cell Freezing Protocol (Freezing Cells, 2013) 
Prepare freezing medium and store at 2° to 8°C until use. Note that the appropriate 
freezing medium depends on the cell line. 
For adherent cells, gently detach cells from the tissue culture vessel following the 
procedure used during the subculture. Resuspend the cells in complete medium required 
for that cell type. 
Determine the total number of cells and percent viability using a hemacytometer, cell 
counter and Trypan Blue exclusion, or the Countess® Automated Cell 
Counter. According to the desired viable cell density, calculate the required volume of 
freezing medium. 
Centrifuge the cell suspension at approximately 100–200 × g for 5 to 10 minutes. 
Aseptically decant supernatant without disturbing the cell pellet.  
Note: Centrifugation speed and duration varies depending on the cell type.  
Resuspend the cell pellet in cold freezing medium at the recommended viable cell density 
for the specific cell type. 
Dispense aliquots of the cell suspension into cryogenic storage vials. As you aliquot 
them, frequently and gently mix the cells to maintain a homogeneous cell suspension. 
Freeze the cells in a controlled rate freezing apparatus, decreasing the temperature 
approximately 1°C per minute. Alternatively, place the cryovials containing the cells in 
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